eFFECTOR Therapeutics initiates Zotatifin Ph2a in breast and lung cancers

Clinical Impact

Aug 4

Written By Frances Benson

https://investors.effector.com/news-releases/news-release-details/effector-therapeutics-initiates-phase-2a-expansion-cohorts

2021

Frances Benson

BioTheryX appoints three new members to its Board of Directors

eFFECTOR Therapeutics doses first COVID- 19 patient in Zotatifin Ph1b trial